

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* BLICKENSTAFF KIM D (Last) (First) (Middle) C/O TANDEM DIABETES CARE, INC. 11075 ROSELLE STREET (Street) SAN DIEGO CA 92121 (City) (State) (Zip)			2. Issuer Name and Ticker or Trading Symbol TANDEM DIABETES CARE INC [TNDM]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)		
			3. Date of Earliest Transaction (Month/Day/Year) 05/17/2022					
			4. If Amendment, Date of Original Filed (Month/Day/Year)			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	05/17/2022		M ⁽¹⁾		6,560	A	\$9	8,452	D	
Common Stock	05/18/2022		M		2,205	A	\$0	10,657	D	
Common Stock	05/17/2022		M ⁽²⁾		13,562	A	\$73.726	215,952	I	See Footnote ⁽³⁾
Common Stock	05/17/2022		S ⁽²⁾		10,762	D	\$92.91	205,190	I	See Footnote ⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option	\$9	05/17/2022		M		6,560		(4)	(5)	Common Stock	6,560	\$9	0	D	
Warrant	\$73.726	05/17/2022		M		13,562		05/17/2022	(6)	Common Stock	13,562	\$73.726	0	I	See Footnote ⁽³⁾
Restricted Stock Unit ⁽⁷⁾	(8)	05/18/2022		M		2,205		(9)	(9)	Common Stock	2,205	\$0	0	D	

Explanation of Responses:

- Represents shares of common stock received upon exercise of a stock option award.
- The transaction reflects the cashless exercise of warrants to purchase common stock, at an exercise price of \$73.726. Pursuant to the terms of the warrant, the shares of common stock were sold at a price equal to the average of the closing prices of the shares over the 30-day period ending three days prior to the date on which the notice of exercise was received by the Issuer.
- The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010.
- The options vested as to twenty-five percent (25%) of the underlying shares on 5/17/2018, and the remaining shares vested in thirty-six (36) equal monthly installments thereafter, subject to the terms of Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan (the 2013 Plan).
- The expiration date for these options is 10 years from the date of grant.
- The expiration dates for these warrants are May 25, 2022 (2,712 shares), and July 3, 2022 (10,850 shares).
- Awarded on May 18, 2021 pursuant to the 2013 Plan, as amended, and the agreements related thereto.
- Each restricted stock (RSU) unit represents a contingent right to receive one share of common stock of the Company.
- Shares will vest on the one year anniversary of the grant date, subject to the terms of the 2013 Plan.

Remarks:

/s/ Rachel Malina, Attorney-in-Fact for 05/19/2022
Kim D. Blickenstaff

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

The undersigned hereby constitutes and appoints Shannon M. Hansen, Leigh A. Vosseller, Christina X. Sun, and Rachel Malina, or any of them singly or jointly, to

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer of Tandem Diabetes Care, Inc. (the "Company"),
- (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such functions,
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to the undersigned.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform each and every act and thing whatsoever that may be necessary or desirable to carry out the foregoing. The undersigned agrees that each such attorney-in-fact may rely entirely on information furnished orally or in writing by the undersigned to the extent of such information.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4s and 5s with respect to the Company. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 21st day of April, 2022.

By:/s/ Kim D. Blickenstaff

Name: Kim D. Blickenstaff
DocuSign